EXPERIMENTAL EVALUATION OF TIGECYCLINE AND TEIKOPLANIN IN THE TREATMENT OF IMPLANT RELATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) OSTEOMYELITIS

Orhan Z., Degirmenci E., Oktas B., Karaduman O., Kir G., DURMUŞOĞLU L.

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, cilt.5, sa.10, ss.4566-4573, 2014 (Hakemli Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 10
  • Basım Tarihi: 2014
  • Doi Numarası: 10.13040/ijpsr.0975-8232.5(10).4566-73
  • Dergi Adı: INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH
  • Sayfa Sayıları: ss.4566-4573
  • Anahtar Kelimeler: MRSA, Experimental implant-related osteomyelitis, Tigecycline, Teicoplanin, IN-VITRO ACTIVITIES, BACTERIAL ADHERENCE, K-WIRES, VANCOMYCIN, GLYCYLCYCLINE, TEICOPLANIN, GAR-936, HYDROXYAPATITE, OSTEOCYTES, CEMENT
  • Marmara Üniversitesi Adresli: Evet

Özet

Treatment of implant related MRSA osteomyelitis is a real challenge both for the physician and the patient. We evaluated the comparative efficacy of tigecycline, a novel broad-spectrum glycycline antibiotic and the glycopeptide antibiotic teicoplanin in the treatment of implant related MRSA osteomyelitis in an experimental rat model. Implant related MRSA osteomyelitis was studied in tibial metaphysis of 60 rats. When compared to the control groups, the number of microorganisms was found to be significantly lower in the study groups, but there was no statistically significant difference between tigecycline and teicoplanin respectively. Tigecycline with its good tissue penetration and lower side effects was found to be as effective as teicoplanin in implant related MRSA osteomyelitis, even if the implant is retained. It could be considered as an alternative to glycopeptides because of the efficacy and because of the lower adverse effects in long term usage. Further studies are warranted to suggest a standard medical treatment for implant-related osteomyelitis.